WaVe生命科学 WVE 深 沪
等待开盘 12-03 09:30:00 美东时间
6.99
-0.420
-5.67%
华盛通- 最 高7.48
- 今 开7.41
- 成交量 230.25万股
- 最 低 6.955
- 昨 收 7.41
- 总市值 11.11亿
- 52周最高 14.57
- 市盈率 静 --
- 换手率 1.45%
- 52周最低 5.28
- 委 比 87.18%
- 总股本 1.59亿
- 历史最高 56.00
- 量 比 1.22
- 振 幅 7.09%
- 历史最低 1.16
- 每 手 1
- 风险率 2.40%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
11-12 11:43
电话会总结 ｜ Wave Life Sciences (WVE) Earnings Transcript
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Wave Life Sciences (WVE) 业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** 2025年录得营收760万美元，相比去年同期的负770万美元实现显著改善，主要归因于与GSK合作协议收入确认时间的影响。 **费用支出：** 研发费用4,590万美元，较去年同期4,120万美元增长11.4%，主要由于抑制剂和RNA编辑项目的推进以及薪酬成本增加；一般管理费用1,810万美元，较去年同期1,500万美元增长20.7%，主要因股权激励和外部费用增加。 **净亏损：** 录得净亏损5,390万美元，相比去年
11-11 12:23
Wave Life Sciences misses Q3 report
Wave Life Sciences press release (WVE): Q3 GAAP EPS of -$0.32 misses by $0.01. Revenue of $7.61M (+-199.1% Y/Y) misses by $2.92M. Cash and cash equivalents were $196.2 million as of September 30, 2025...
11-10 20:42
WAVE Life Sciences Q3 EPS $(0.32) Misses $(0.30) Estimate, Sales $7.608M Miss $11.130M Estimate
WAVE Life Sciences (NASDAQ:WVE) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.30) by 5.26 percent. This is a 31.91 percent increase over losses of $(0.47) per share
11-10 20:33
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
11-10 19:12
A Look Ahead: WAVE Life Sciences's Earnings Forecast
WAVE Life Sciences (NASDAQ:WVE) will release its quarterly earnings report on M...
11-08 01:03
Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
Wave Life Sciences announced promising results from its INLIGHT clinical trial of WVE-007, a GalNAc-siRNA for obesity treatment. The trial showed dose-dependent reductions of Activin E, up to 85%, with the lowest dose maintaining effects for six months, suggesting potential for annual dosing. WVE-007 was also found to be safe and well-tolerated. The company expects additional clinical data updates in late 2025 and throughout 2026. Additionally, W...
10-29 20:15
Wave Life Sciences Advances WVE-006 Study for AATD Treatment
Wave Life Sciences Pte. Ltd (($WVE)) announced an update on their ongoing clini...
10-28 05:53
Analysts’ Top Healthcare Picks: Climb Bio (CLYM), Wave Life Sciences (WVE)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
10-16 19:20
